Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Identifieur interne : 000880 ( Main/Exploration ); précédent : 000879; suivant : 000881Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Auteurs : Ajinkya Pawar [États-Unis] ; Rishi J. Desai [États-Unis] ; Daniel H. Solomon [États-Unis] ; Adrian J. Santiago Ortiz [États-Unis] ; Sara Gale [États-Unis] ; Min Bao [États-Unis] ; Khaled Sarsour [États-Unis] ; Sebastian Schneeweiss [États-Unis] ; Seoyoung C. Kim [États-Unis]Source :
- Annals of the rheumatic diseases [ 1468-2060 ] ; 2019.
Descripteurs français
- KwdFr :
- Abatacept (effets indésirables), Abatacept (usage thérapeutique), Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés (effets indésirables), Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (effets indésirables), Antirhumatismaux (usage thérapeutique), Bases de données factuelles, Comorbidité, Femelle, Hospitalisation (), Humains, Infections bactériennes (), Infections bactériennes (épidémiologie), Infections opportunistes (), Infections opportunistes (épidémiologie), Maladies virales (), Maladies virales (épidémiologie), Mâle, Polyarthrite rhumatoïde (traitement médicamenteux), Polyarthrite rhumatoïde (épidémiologie), Produits biologiques (effets indésirables), Produits biologiques (usage thérapeutique), Sujet âgé, États-Unis d'Amérique (épidémiologie), Études de cohortes, Évaluation des risques ().
- MESH :
- effets indésirables : Abatacept, Anticorps monoclonaux humanisés, Antirhumatismaux, Produits biologiques.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- usage thérapeutique : Abatacept, Anticorps monoclonaux humanisés, Antirhumatismaux, Produits biologiques.
- épidémiologie : Infections bactériennes, Infections opportunistes, Maladies virales, Polyarthrite rhumatoïde, États-Unis d'Amérique.
- Adulte, Adulte d'âge moyen, Bases de données factuelles, Comorbidité, Femelle, Hospitalisation, Humains, Infections bactériennes, Infections opportunistes, Maladies virales, Mâle, Sujet âgé, Études de cohortes, Évaluation des risques.
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Abatacept (adverse effects), Abatacept (therapeutic use), Adult, Aged, Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (adverse effects), Antirheumatic Agents (therapeutic use), Arthritis, Rheumatoid (drug therapy), Arthritis, Rheumatoid (epidemiology), Bacterial Infections (chemically induced), Bacterial Infections (epidemiology), Biological Products (adverse effects), Biological Products (therapeutic use), Cohort Studies, Comorbidity, Databases, Factual, Female, Hospitalization (statistics & numerical data), Humans, Male, Middle Aged, Opportunistic Infections (chemically induced), Opportunistic Infections (epidemiology), Risk Assessment (methods), Tumor Necrosis Factor Inhibitors (adverse effects), United States (epidemiology), Virus Diseases (chemically induced), Virus Diseases (epidemiology).
- MESH :
- chemical , adverse effects : Abatacept, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Biological Products, Tumor Necrosis Factor Inhibitors.
- chemical , therapeutic use : Abatacept, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Biological Products.
- geographic , epidemiology : United States.
- chemically induced : Bacterial Infections, Opportunistic Infections, Virus Diseases.
- drug therapy : Arthritis, Rheumatoid.
- epidemiology : Arthritis, Rheumatoid, Bacterial Infections, Opportunistic Infections, Virus Diseases.
- methods : Risk Assessment.
- statistics & numerical data : Hospitalization.
- Adult, Aged, Cohort Studies, Comorbidity, Databases, Factual, Female, Humans, Male, Middle Aged.
Abstract
To investigate the rate of serious bacterial, viral or opportunistic infection in patients with rheumatoid arthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis factor inhibitors (TNFi) or abatacept.
DOI: 10.1136/annrheumdis-2018-214367
PubMed: 30679153
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000520
- to stream PubMed, to step Curation: 000520
- to stream PubMed, to step Checkpoint: 000349
- to stream Ncbi, to step Merge: 001D82
- to stream Ncbi, to step Curation: 001D82
- to stream Ncbi, to step Checkpoint: 001D82
- to stream Main, to step Merge: 000880
- to stream Main, to step Curation: 000880
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.</title><author><name sortKey="Pawar, Ajinkya" sort="Pawar, Ajinkya" uniqKey="Pawar A" first="Ajinkya" last="Pawar">Ajinkya Pawar</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Desai, Rishi J" sort="Desai, Rishi J" uniqKey="Desai R" first="Rishi J" last="Desai">Rishi J. Desai</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Solomon, Daniel H" sort="Solomon, Daniel H" uniqKey="Solomon D" first="Daniel H" last="Solomon">Daniel H. Solomon</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Santiago Ortiz, Adrian J" sort="Santiago Ortiz, Adrian J" uniqKey="Santiago Ortiz A" first="Adrian J" last="Santiago Ortiz">Adrian J. Santiago Ortiz</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Gale, Sara" sort="Gale, Sara" uniqKey="Gale S" first="Sara" last="Gale">Sara Gale</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Bao, Min" sort="Bao, Min" uniqKey="Bao M" first="Min" last="Bao">Min Bao</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Sarsour, Khaled" sort="Sarsour, Khaled" uniqKey="Sarsour K" first="Khaled" last="Sarsour">Khaled Sarsour</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Schneeweiss, Sebastian" sort="Schneeweiss, Sebastian" uniqKey="Schneeweiss S" first="Sebastian" last="Schneeweiss">Sebastian Schneeweiss</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Kim, Seoyoung C" sort="Kim, Seoyoung C" uniqKey="Kim S" first="Seoyoung C" last="Kim">Seoyoung C. Kim</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA sykim@bwh.harvard.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country><wicri:regionArea>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30679153</idno><idno type="pmid">30679153</idno><idno type="doi">10.1136/annrheumdis-2018-214367</idno><idno type="wicri:Area/PubMed/Corpus">000520</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000520</idno><idno type="wicri:Area/PubMed/Curation">000520</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000520</idno><idno type="wicri:Area/PubMed/Checkpoint">000349</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000349</idno><idno type="wicri:Area/Ncbi/Merge">001D82</idno><idno type="wicri:Area/Ncbi/Curation">001D82</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D82</idno><idno type="wicri:Area/Main/Merge">000880</idno><idno type="wicri:Area/Main/Curation">000880</idno><idno type="wicri:Area/Main/Exploration">000880</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.</title><author><name sortKey="Pawar, Ajinkya" sort="Pawar, Ajinkya" uniqKey="Pawar A" first="Ajinkya" last="Pawar">Ajinkya Pawar</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Desai, Rishi J" sort="Desai, Rishi J" uniqKey="Desai R" first="Rishi J" last="Desai">Rishi J. Desai</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Solomon, Daniel H" sort="Solomon, Daniel H" uniqKey="Solomon D" first="Daniel H" last="Solomon">Daniel H. Solomon</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Santiago Ortiz, Adrian J" sort="Santiago Ortiz, Adrian J" uniqKey="Santiago Ortiz A" first="Adrian J" last="Santiago Ortiz">Adrian J. Santiago Ortiz</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Gale, Sara" sort="Gale, Sara" uniqKey="Gale S" first="Sara" last="Gale">Sara Gale</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Bao, Min" sort="Bao, Min" uniqKey="Bao M" first="Min" last="Bao">Min Bao</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Sarsour, Khaled" sort="Sarsour, Khaled" uniqKey="Sarsour K" first="Khaled" last="Sarsour">Khaled Sarsour</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Schneeweiss, Sebastian" sort="Schneeweiss, Sebastian" uniqKey="Schneeweiss S" first="Sebastian" last="Schneeweiss">Sebastian Schneeweiss</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Kim, Seoyoung C" sort="Kim, Seoyoung C" uniqKey="Kim S" first="Seoyoung C" last="Kim">Seoyoung C. Kim</name><affiliation wicri:level="2"><nlm:affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA sykim@bwh.harvard.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country><wicri:regionArea>Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><series><title level="j">Annals of the rheumatic diseases</title><idno type="eISSN">1468-2060</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abatacept (adverse effects)</term><term>Abatacept (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (adverse effects)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Arthritis, Rheumatoid (epidemiology)</term><term>Bacterial Infections (chemically induced)</term><term>Bacterial Infections (epidemiology)</term><term>Biological Products (adverse effects)</term><term>Biological Products (therapeutic use)</term><term>Cohort Studies</term><term>Comorbidity</term><term>Databases, Factual</term><term>Female</term><term>Hospitalization (statistics & numerical data)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Opportunistic Infections (chemically induced)</term><term>Opportunistic Infections (epidemiology)</term><term>Risk Assessment (methods)</term><term>Tumor Necrosis Factor Inhibitors (adverse effects)</term><term>United States (epidemiology)</term><term>Virus Diseases (chemically induced)</term><term>Virus Diseases (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abatacept (effets indésirables)</term><term>Abatacept (usage thérapeutique)</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antirhumatismaux (effets indésirables)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Bases de données factuelles</term><term>Comorbidité</term><term>Femelle</term><term>Hospitalisation ()</term><term>Humains</term><term>Infections bactériennes ()</term><term>Infections bactériennes (épidémiologie)</term><term>Infections opportunistes ()</term><term>Infections opportunistes (épidémiologie)</term><term>Maladies virales ()</term><term>Maladies virales (épidémiologie)</term><term>Mâle</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Polyarthrite rhumatoïde (épidémiologie)</term><term>Produits biologiques (effets indésirables)</term><term>Produits biologiques (usage thérapeutique)</term><term>Sujet âgé</term><term>États-Unis d'Amérique (épidémiologie)</term><term>Études de cohortes</term><term>Évaluation des risques ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Abatacept</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Biological Products</term><term>Tumor Necrosis Factor Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Abatacept</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Biological Products</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Bacterial Infections</term><term>Opportunistic Infections</term><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Abatacept</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Produits biologiques</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Bacterial Infections</term><term>Opportunistic Infections</term><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Risk Assessment</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Abatacept</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Produits biologiques</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections bactériennes</term><term>Infections opportunistes</term><term>Maladies virales</term><term>Polyarthrite rhumatoïde</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Cohort Studies</term><term>Comorbidity</term><term>Databases, Factual</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Bases de données factuelles</term><term>Comorbidité</term><term>Femelle</term><term>Hospitalisation</term><term>Humains</term><term>Infections bactériennes</term><term>Infections opportunistes</term><term>Maladies virales</term><term>Mâle</term><term>Sujet âgé</term><term>Études de cohortes</term><term>Évaluation des risques</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To investigate the rate of serious bacterial, viral or opportunistic infection in patients with rheumatoid arthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis factor inhibitors (TNFi) or abatacept.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Pawar, Ajinkya" sort="Pawar, Ajinkya" uniqKey="Pawar A" first="Ajinkya" last="Pawar">Ajinkya Pawar</name></region><name sortKey="Bao, Min" sort="Bao, Min" uniqKey="Bao M" first="Min" last="Bao">Min Bao</name><name sortKey="Desai, Rishi J" sort="Desai, Rishi J" uniqKey="Desai R" first="Rishi J" last="Desai">Rishi J. Desai</name><name sortKey="Gale, Sara" sort="Gale, Sara" uniqKey="Gale S" first="Sara" last="Gale">Sara Gale</name><name sortKey="Kim, Seoyoung C" sort="Kim, Seoyoung C" uniqKey="Kim S" first="Seoyoung C" last="Kim">Seoyoung C. Kim</name><name sortKey="Santiago Ortiz, Adrian J" sort="Santiago Ortiz, Adrian J" uniqKey="Santiago Ortiz A" first="Adrian J" last="Santiago Ortiz">Adrian J. Santiago Ortiz</name><name sortKey="Sarsour, Khaled" sort="Sarsour, Khaled" uniqKey="Sarsour K" first="Khaled" last="Sarsour">Khaled Sarsour</name><name sortKey="Schneeweiss, Sebastian" sort="Schneeweiss, Sebastian" uniqKey="Schneeweiss S" first="Sebastian" last="Schneeweiss">Sebastian Schneeweiss</name><name sortKey="Solomon, Daniel H" sort="Solomon, Daniel H" uniqKey="Solomon D" first="Daniel H" last="Solomon">Daniel H. Solomon</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000880 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000880 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30679153
|texte= Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30679153" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |